8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 30, 2013

GENSPERA, INC.

(Exact name of registrant as specified in Charter)

Delaware	0001421204	20-0438951
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(IRS Employee Identification No.)

2511 N Loop 1604 W, Suite 204

San Antonio, TX 78258

(Address of Principal Executive Offices)

210-479-8112

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On October 30, 2013, a representative of GenSpera, Inc. (the “Company”) presented a company overview at the New York Society of Security Analysts (NYSSA) Life Science Conference held at the NYSSA Conference Center, located at 1540 Broadway, Suite 1010 New York, NY. Filed herewith as Exhibit 99.01 are the slides that were presented at the conference.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in the exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.01	Slides presented at the New York Society of Security Analysts Life Science Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 30, 2013

GenSpera, Inc.
By:	/s/ Craig Dionne
	Craig Dionne Chief Executive Officer

INDEX OF EXHIBITS

Exhibit No.	Description
99.01	Slides presented at the New York Society of Security Analysts Life Science Conference

EX-99.1

Specific targeting of tumors using a potent, unique prodrug GNSZ OCTOBER 2013

SAFE HARBOR STATEMENT GNSZ | OCTOBER 2013 PAGE 2 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward - looking statements, which may include, but are not limited to, factors related to GenSpera's anticipated growth strategies, the outcome of its clinical trials, future business development, ability to develop new products, expand to other related industries or markets in other geographical locations, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. Readers are advised that this information is intended for the use of investment professionals. Anyone interested in obtaining information on GenSpera should contact GenSpera to receive GenSpera's most recent financial reports. This presentation was developed by GenSpera and is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company's stock. This presentation is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of presentation and are subject to change without notice.

GENSPERA OVERVIEW GNSZ | OCTOBER 2013 PAGE 3 Highly differentiated, targeted therapeutic agent with encouraging clinical data • Platform technology developed at Johns Hopkins • Lead drug candidate, G - 202, is designed to be activated only within tumor • Novel mechanism of tumor killing, benign side effect profile • G - 202 is expected to be active in a wide range of tumor types • Completed Phase I with encouraging data in liver cancer • Phase II ongoing in liver cancer patients - preliminary data expected Q2 2014

A NOVEL CYTOTOXIN GNSZ | OCTOBER 2013 PAGE 4 • Active toxic ingredient from Thapsia garganica – a Mediterranean plant used for centuries in folk remedies • Unique molecular mechanism of action • Potent inhibitor of the intracellular SERCA pump - causes Ca2 + (calcium) to rise significantly and trigger apoptosis (cell death) • Kills cancer cells independent of growth rate • Completely indiscriminate – must be delivered directly to tumor Thapsigargin

PSMA IS EXPRESSED BY TUMOR VASCULATURE GNSZ | OCTOBER 2013 PAGE 5 Normal Pancreas Normal Skin Normal Lung Normal Bladder Pancreatic Cancer Bladder Cancer Lung Cancer Skin Cancer

G202: A PSMA - ACTIVATED THAPSIGARGIN PRODRUG GNSZ | OCTOBER 2013 PAGE 6 O O H OH CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 H N N H H N N H H N N H H N N H O O NH 2 O O O H 2 N O HO O OH O HN N N O O H N O (CH 2 ) 11 His (H) Ser- (S) Ser- (S) Lys- (K) Leu- (L) Gln- (Q) Leu- (L)12ADT - PSA Hydrolysis O O H OH CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 H N N H H N N H H N N H H N N H O O NH 2 O O O H 2 N O HO O OH O HN N N O O H N O (CH 2 ) 11 His (H) Ser- (S) Ser- (S) Lys- (K) Leu- (L) Gln- (Q) Leu- (L)12ADT - O O H OH CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 O O H OH CH 3 CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 H N N H H N N H H N N H H N N H O O NH 2 O O O H 2 N O HO O OH O HN N N O O H N O H N N H H N N H H N N H H N N H O O NH 2 O O O H 2 N O HO O OH O HN N N O O H N O (CH 2 ) 11 His (H) Ser- (S) Ser- (S) Lys- (K) Leu- (L) Gln- (Q) Leu- (L)12ADT - PSA Hydrolysis O O H OH CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 (CH 2 ) 11 12ADT- NH O O O ONH 2 OH H N N H O HO O H N OH O HO O O HO O NH O O O ONH 2 OH H N N H O HO O H N OH O HO O O HO O -N H Asp Glu Glu Glu Glu PSMA Hydrolysis O O H OH CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 O O H OH CH 3 CH 3 OH O CH 3 O O O O O CH 3 O H 3 C O H 3 8 1 (CH 2 ) 11 12ADT- NH O O O ONH 2 OH H N N H O HO O H N OH O HO O O HO O NH O O O ONH 2 OH H N N H O HO O H N OH O HO O O HO O -N H Asp Glu Glu Glu Glu PSMA Hydrolysis

"MOLECULAR GRENADES" GNSZ | OCTOBER 2013 PAGE 7 Active drug (12ADT) with a targeting/masking agent attached (i.e., the prodrug) is inactive in blood stream – like a grenade with pin intact… …until it finds an enzyme which is found only at “target site.” Contact with the enzyme “pulls the pin” off the targeting/masking agent. The active drug, no longer soluble, “precipitates” directly into nearby cells and destroys them. Normal Normal Target Cell

HEPATOCELLULAR CARCINOMA GNSZ | OCTOBER 2013 PAGE 8 • Hepatocellular carcinoma (HCC) is the most common type of liver cancer • 6 th most common type of cancer worldwide and 3 rd most common cause of cancer deaths worldwide • 75% of HCC patients are in Asia - Pacific Rim with ~360,000 deaths annually • Only one approved drug (Nexavar®) – gives ~ 2 - 3 month increase in median survival

G - 202 PHASE I RESULTS GNSZ | OCTOBER 2013 PAGE 9 • Recommended dosing regimen: IV infusion, 40 mg/m 2 on Day 1, 66.8 mg/m 2 on Days 2 and 3 of 28 - day schedule with hydration and standard pre - medications • Side Effect Profile: Easily managed minimal side effects (fatigue, nausea on Day 1, rash, transient small elevation in serum creatinine). No significant effect on liver, bone marrow or cardiovascular system.

G - 202 PHASE Ib : Results in Patients with HCC GNSZ | OCTOBER 2013 PAGE 10 Time to Progression (TTP) Month 1 2 3 4 5 6 7 8 9 10 11 12 Patient A B C D E Median time to progression after failure on Nexavar® therapy in patients with advanced HCC (liver cancer) is ~2.1 months.

G - 202 PHASE II LIVER CANCER GNSZ | OCTOBER 2013 PAGE 11 • Population: Patients with progressive advanced hepatocellular cancer (HCC) following Nexavar® therapy • Dosing Regimen: IV administration on Days 1 - 3 of 28 - day schedule • Primary Endpoint: Time to disease progression (TTP) • Number of Patients: up to 29 patients (9 enrolled to date) • Interim Data Available: Expected Q2 2014

FINANCIAL OVERVIEW GNSZ | OCTOBER 2013 PAGE 12 • Raised $24M since November 2007 – majority of capital from repeat investors • ~$5M on hand – burn rate ~ $1M per quarter • ~27M common issued and outstanding • ~17M warrants and options • Management & Scientific Advisory Board own ~23% Cash Stock

SUMMARY AND MILESTONES GNSZ | OCTOBER 2013 PAGE 13 • G - 202 is a targeted agent with a unique mechanism of action and benign side effect profile • Encouraging Phase I human clinical data in liver cancer • Phase II liver cancer trial underway - preliminary data expected in Q2 2014 • Phase II glioblastoma trial to begin Q1 2014 • Anticipated out - license or partnering subsequent to Phase II

Specific targeting of tumors using a potent, unique prodrug GNSZ OCTOBER 2013